The new system, now approved by the FDA, uses robotics and software algorithms to speed up the testing process and can provide six to eight hours of uninterrupted processing — which would normally require multiple lab technician interactions.
The BD COR System will initially be available with the BD Onclarity HPV Assay and can be used by the high-throughput labs that process most cervical cancer screening specimens in the U.S.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
